AU698455B2

AU698455B2 - 5H-thiazolo{3,2-a}pyrimidin-5-one derivatives

Info

Publication number: AU698455B2
Application number: AU58203/96A
Authority: AU
Inventors: Lluis Anglada; Josep M Castello; Rafael Foguet; Jose A Ortiz; Aurelio Sacristan
Original assignee: Ferrer Internacional SA
Current assignee: Ferrer Internacional SA
Priority date: 1995-05-26
Filing date: 1996-05-24
Publication date: 1998-10-29
Anticipated expiration: 2016-05-24
Also published as: ES2097093A1; WO1996037498A1; IL118280A0; ZA964091B; TW430666B; EP0773947A1; ATE196633T1; PT773947E; IL118280A; AU5820396A; NO970327D0; EP0773947B1; CA2195578A1; NO308304B1; DE69610477T2; MX9601953A; DE69610477D1; NO970327L; NZ308533A; US5798361A

Abstract

PCT No. PCT/EP96/02254 Sec. 371 Date Mar. 14, 1997 Sec. 102(e) Date Mar. 14, 1997 PCT Filed May 24, 1996 PCT Pub. No. WO96/37498 PCT Pub. Date Nov. 28, 1996The present invention relates to new 5H-thiazolo[3,2-a]pyrimidin -5-one derivatives having the formula (I): <IMAGE> (I) wherein Ar is phenyl optionally substituted by one or two groups selected from halogen, alkyl having from 1 to 4 carbon atoms, methylendioxy, alkoxy having from 1 to 4 carbon atoms, and trifluoromethyl; and R is a group selected from (a) or (b): <IMAGE> (a) <IMAGE> (b) as well as their pharmaceutically acceptable addition salts, which are useful in the treatment of psychosis, schizophrenia and anxiety. This invention also discloses methods and intermediates for their preparation and pharmaceutical compositions containing them.

Description

5H-THIAZ0L0 [3,2-a] PYRIMIDIN-5-0NE DERIVATIVES

The present inwention relates to new 5H- thiazolo [3 , 2 - a] pyrimidin- 5 - one derivatives having the formula ( I ) :

( I ) wherein Ar is phenyl optionally substituted by. one or two groups selected from halogen, alkyl having from 1 to 4 carbon atoms, methylendioxy, alkoxy having from 1 to 4 carbon atoms, and trifluoromethyl; and R is a group selected from (a) or

(b) :

(a) (b)

as well as their pharmaceutically acceptable addition salts.

The compounds of the present invention are obtained by reacting 3-aryl-6- (2-substituted ethyl)-7-methyl-thiazolo[3,2- a]pyrimidin-5-one of general formula (II) , wherein Ar is as defined for (I) and X is a halogen selected from chlorine, bromine or iodine, or a sulfonyloxy group, e.g., methylsulfonyloxy, p-toluensulfonyloxy and the like, with a piperidine of general formula (III) wherein R is as defined for (I) according to Scheme 1:

Scheme 1

(III)

(ID

(I)

The reaction can conveniently be conducted in an inert organic solvent such as, for example, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile and the like, and in the presence of a base such as, for example, alkali metal carbonates, acid carbonates, alkoxides or hydrides. The addition of catalytic amounts of an alkali metal iodide enhances the reaction.

In turn, the intermediates of general formula (II) are prepared by reacting the corresponding 4-aryl-2-thiazolamines of general formula (IV) , wherein Ar is as defined for the foregoing structures, with 2-acetylbutyrolactone, and then by halogenation or sulfonation of 3-aryl-6- (2-hydroxyethyl) -7- methyl-thiazolo[3,2-a]pyrimidin-5-ones (V) according to Scheme 2: Scheme 2

(IV)

(V)

The foregoing procedure may occasionally be carried out without isolating the intermediates of general formula (V) . Standard halogenating agents which may be used for the halogenation of (V) include phosphorus oxychloride, phosphorus oxybromide, phosphorus trichloride, phosphorus tribromide, phosphorus pentachloride, phosphorus pentabromide, thionyl chloride, t-butyl hypochlorite and the like. Standard sulfonating agents which may be used for the sulfonation of (V) include methylsulfonyl chloride, p- toluensulfonyl chloride and the like.

The intermediates of general formula (II) when X is chlorine will be hereinafter designated with the general formula (VI) :

CH₂-

(VI) wherein Ar is as defined for the foregoing structures. These compounds are very appropriate for the procedure in Scheme 2. Due to the fact that such new intermediates are described for the first time, the scope of the present invention will also be referred to them.

As the background of the present invention there are cited European Patent No. 0196132 where the preparation of 1,2- benzisoxazol-3-yl and 1,2-benzisothiazol-3-il derivatives, and their use in the treatment of psychotic diseases and of those other diseases which serotonin release is of predominant importance are described; and US Patent No. 4443451 where the preparation of bicyclic pyrimidin-5-one derivatives and their use as psychotropic agents are described.

The biochemical assays demonstrate that the compounds of the present invention possess a strong activity on receptors involved in the neuroleptic action (D₂ and 5HT₂) (B. A. cMillen et al. , "Drug Dev. Res.", 12, 53-62, 1988).

Specific binding to D₂ and 5HT₂ receptors was tested as follows:

P., receptors: A 2-nM solution of radioactive spiperone ( [³H]spiperone) , which acts as a specific ligand, was incubated with the membrane corresponding to 20 mg of rat striatum for 20 min at 35°C buffered at pH 7.4 with Tris.HCl. The non-specific binding was then determined by addition of a micromolar concentration of unlabelled spiperone. IC₅₀ (inhibitory concentration 50%) was calculated from the inhibition rate of the specific binding obtained by addition of eleven different concentrations of the compounds to be tested. After the incubation was completed, the sample was filtered through a glass fiber filter and then washed three times with Tris.HCl buffer. The amount of receptor-bound radioactivity was retained on the membrane and determined by liquid scintillation counting.

5HT_: receptors: A 0.5 nM solution of radioactive ketanserin ( [³H]ketanserin, which acts as a specific ligand, was incubated with the membrane corresponding to 1 mg of rat cortex for 30 min at 35°C buffered at pH 7.4 with Tris.HCl. Non-specific binding was then determined by addition of 5 micromolar concentration of unlabelled mianserin. IC₅₀ (inhibitory concentration 50%) was calculated from the inhibition rate of the specific binding obtained by addition of eleven different concentrations of the compounds to be tested. After the incubation was completed, the sample was filtered through a glass fiber filter and then washed three times with Tris.HCl buffer. The amount of receptor-bound radioactivity was retained on the membrane and determined by liquid scintillation counting.

The results from the specific binding to D₂ and 5HT₂ receptors are presented as IC₅₀ (M) in Table 1. Table 1 - IC₅₀ (M)

Code Compound (I) D₂ 5HT₂ D,/HT₂

FI-8510 Example 14 1.97xl0-⁸ 3.18X10^"9 6.2

FI-8525 Example 15 4.4lxl0^"8 3.94x10^"9 11.2

FI-8542 Example 16 4.21X10^"8 8.32X10^"9 5.1

FI-8544 Example 17 3.64xl0^"8 1.49X10^"8 2.4

FI-8543 Example 18 1.73X10^"8 7.63x10^"9 2.3

FI-8545 Example 19 4.36X10-⁸ l.llxlO^"8 3.9

FI-8546 Example 20 1.94xl0^"8 3.52X10^"8 0.6

FI-8568 Example 21 1.66X10-⁸ 2.45X10^"8 0.7

FI-8570 Example 22 2.80x10^"* 7.46x10^"9 3.8

FI-8569 Example 23 2.23xl0^"8 3.2lxl0^"8 0.7

FI-8567 Example 24 2.92xl0^"8 2.95x10^"8 1.0

FI-8571 Example 25 2.09X10^"8 8.33x10^"* 0.3

FI-8572 Example 26 8.20X10^"8 3.5lxl0^"9 23.4

FI-8547 Example 27 1.74X10^"7 1.25x10^"* 13.9

FI-8548 Example 28 7.99x10^"8 8.26x10^"9 9.7

Haloperidol 1.39x10^"* 1.04X10^"7 0.1

From the results of the above table, it can be concluded that the compounds of this invention are characterized by a genuine neuroleptic profile as a result of their specificity on 5HT_: receptors against D₂ receptors according to D_:/5HT₂ ratios which is advantageously higher than that of Haloperidol. This provides the compounds with little possibility to cause extrapyramidal effects at the therapeutic doses.

In Animal Pharmacology Studies, the antipsychotic activity of the compounds was tested by the inhibition of apomorphine-induced climbing behaviour (P.Protais et al: "Psychopharmacology" , 5JD, 1-6, 1976), and their activity on 5HT₂ receptors by the inhibition test of l-(2,5- dimethoxy-4-iodophenyl) -2-aminopropane (DOI) -induced head twitches and scratches (M.Oka et al: "J.Pharm.Exp.Ther. ", 264.(1), 158-165, 1993). The inhibiton test of apomorphine- induced climbing behaviour and the inhibition test of DOI- induced head twitches and scratches are hereinafter described.

Inhibition of apomorphine-induced climbing behaviour: Male Swiss mice weighing 22-24 g were used. One week prior to experiment, animals were kept in our facilities at a temperature of 20-22°C and 12/12 h light-dark cycle, and had free access to food and water. Two hours prior to experiment, the animals were placed in individual cages without access to food.

Animals were administered orally with test drug or 0.25% agar at time 0. After 60 minutes, apomorphine was subcutaneously injected at a dose of 1 mg/kg, and after further 70 minutes the animal's behaviour was assessed. Two additional assessments were performed at 10-min intervals. For assessment, each animal was placed on the bottom of a small upright box (11x7.5x4.5 cm) . The walls of the box were made of translucent methacrylate except one of the lateral surfaces (7.5 cm wide) which was a 3-mm wire mesh. The position of the animal was scored for 2 minutes according to the following criteria: 0 = four paws on the floor; 1 = three paws on the floor; 2 = two paws on the floor; 3 = one paw on the floor; and 4 = four paws holding the wire mesh. If an animal keeps several positions within the 2-min observation, the seconds elapsed in each position will be recorded. Finally, mean scoring was calculated.

Under these experimental conditions, the effective dose 50%

(ED₅₀) values are shown in Table 2.

Inhibition of DPI-induced head twitches and scratches: Male N.M.R.I, mice weighing 22-26 g were used. After the animals were weighed, they were individually placed in transparent cages two hours prior to experiment. Test compound was given p.o. at time 0. The administration interval time between mice was 5 min. At time 60 min DOI at the dose of 3 mg/kg i.p. dissolved in saline was administered. The number of head twitches and scratches were assessed as well as the presence or absence of escape attempts. The effective dose 50% (ED₅₀) values obtained under the above experimental conditions are shown in Table 2.

Similarly, it was proved that by oral route in Sprague- Dawley rats, 50% of treated animals showed catalepsy (ED_S0, mg/kg) according to the values in Table 2.

Table 2 - ED₅₀ (mg/kg)

Code Compound(I) Climbing DOI Catalepsy R*

FI-8510 Example 14 2.9 0.28 9.3 3.2

FI-8525 Example 15 14.7 0.58 16 1.1

FI-8542 Example 16 7.4 0.84 30 4.1

FI-8544 Example 17 3.9 0.57 22.5 5.8

FI-8543 Example 18 7.7 0.80 20 2.6

FI-8545 Example 19 3.5 0.82 9.5 2.7

FI-8570 Example 22 19.0 1.10 40 2.1

FI-8567 Example 24 >50 1.50 >50

FI-8572 Example 26 >50 0.42 >50

FI-8547 Example 27 >50 1.20 >50

FI-8548 Example 28 24.6 0.60 >50 >2.0

Haloperidol 1.2 1.5 1.95 1.6

* R = Catalepsy/Climbing

According to the above table and on the basis of the Catalepsy/Binding (R) ratio, some compounds of the present invention surprisingly exhibit a higher therapeutic margin than that of Haloperidol, which makes them be potentially safer. This fact confirms the higher selectivity of the compounds in 5HT₂ receptors against D₂ receptors found in the biochemical assays. Furthermore, in another independent pharmacological study, anti-DOI test, the pharmacological action on 5HT₂ receptors was higher in several compounds of the present invention than in Haloperidol.

Example 1: 3- (4-methylphenyl) -6- (2-chloroethyl) -7-methyl- thiazolo[3,2-a]pyrimidin-5-one

5.7 g (30 mmoles) of 2-amino-4- (4-met ylphenyl) -thiazol were dissolved in 11 ml (120 mmoles) of phosphorus oxychloride. To the solution formed, 3.25 ml (30 mmoles) of 2-acetyl-butyrolactone were slowly added. The mixture was refluxed for 2 hours, allowed to cool and poured onto 100 g of ice, then basified to pH 9 by adding sodium hydroxide and extracted twice with 100 ml of methylene chloride each time. The organic phase was washed twice with 50 ml of water each time and dried, and the solvent was removed by reduced pressure distillation. The residue formed was purified on a silica gel column using methylene chloride as eluent. 3.4 g of 3- (4-methylphenyl) -6- (2- chloroethyl) -7-methyl-thiazolo[3,2-a]pyrimidin-5-one were obtained as a yellowish solid, mp 152-165^βC. Examples 2 - 13 : Following the same procedure as for the compound in Example 1 and starting from appropriate 4 - aryl - 2 - thiazol - amines , 3 - aryl - 6 - ( 2 - chloroethyl ) - 7 -methyl - thiazolo [3 , 2 -a] pyrimidin- 5 -ones in Table 3 were obtained.

Table 3

Compound (VI) Ar mp ^°C

Example 2 4-fluorophenyl 155.8-158

Example 3 phenyl 134.5-136.4

Example 4 4-methoxypheny1 150.7-152.5

Example 5 4-chlorophenyl 161-163.5

Example 6 3,4-dichlorophenyl 124-128

Example 7 3-chlorophenyl 105-110

Example 8 3-methoxypheny1 129-132

Example 9 3-methylphenyl 97-101

Example 10 3-trifluoromethylphenyl 128-129.5

Example 11 2-fluorophenyl 160-164

Example 12 3-benzo[l, 3] dioxol-5-yl 179-185.2

Example 13 2-chlorophenyl 210-213 Example 14 : 6- [2- [4- ( 6- f luoro- 1 , 2 -benzisoxazol - 3 -yl) -1- piperidinyl] ethyl] -3- (4-fluorophenyl) - 7 -methyl - 5H- thiazolo [3 , 2 -a] pyrimidin-5-one (FI-8510)

In 190 ml of N, N- dimethyl formamide, 13.3 g (41.2 mmoles) of 3- (4 -fluorophenyl) -6- (2-chloroethyl) -7 -methyl -thiazol

[3,2-a]pyrimidin-5-one, 9.1 g (41.2 mmoles) de 6-fluoro-3-

(4-piperidinyl) -benzisoxazol, 18.2 g (131.7 mmoles) of potassium carbonate and a catalytic amount of potassium iodide were suspended. The reaction mixture was heated for 18 hours at a temperature ranging between 85 and 90°C, cooled to 20°C and poured into 400 ml of water. The solid formed was purified on silica gel column, using acetonitrile/methanol as eluent. 8.5 g of 6- [2- [4- (6- fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl]ethyl] -3- (4- fluorophenyl) -7-methyl-5H-thiazolo [3,2-a]pyrimidin-5-one were obtained, mp 119-122°C.

Example 15: 6- [2- [4- (6-fluoro-1,2-benzisoxazol-3-yl) -1- piperidinyl]ethyl] -3-phenyl-7-methyl-5H-thiazolo[3,2-a] pyrimidin-5-one (FI-8525)

In 50 ml de N,N-dimethylformamide, 3.12 g (10.2 mmoles) of 3-phenyl-6- (2-chloroethyl) -7-methyl-thiazolo [3,2-a] pyrimidin-5-one, 2.23 g (10.2 mmoles) of 6-fluoro-3- (4- piperidinyl) -benzisoxazol, 4.50 g (32.5 mmoles) of potassium carbonate and a catalytic amount of potassium iodide were suspended. The reaction mixture was heated for 18 hours at a temperature ranging between 85 and 90°C, cooled to 2θ^"C and poured into 100 ml of water. The solid^' formed was purified on silica gel column, using acetonitrile/methanol as eluent. 2.1 g of 6- [2- [4- (6- fluoro-1, 2-benzisoxazol-3-yl) - 1-piperidinyl] ethyl] -3- phenyl-7-methyl-5H-thiazolo [3, 2-a]pyrimidin-5-one, mp 76- 91^°C.

Example 16: 6- [2- [4- (6-fluoro-1,2-benzisoxazol-3-yl) -1- piperidinyl] ethyl] -3- (4 - ethoxyphenyl) - 7 -methyl - 5H- thiazolo[3,2-a]pyrimidin-5-one (FI-8542)

In 20 ml of acetonitrile, 1.34 g (4 mmoles) of 3- (4- methoxyphenyl) -6- (2-chloroethyl) -7-methyl-thiazolo [3,2-a] pyrimidin-5-one, 1.03 g (4 mmoles) of 6-fluoro-3- (4- piperidinyl) -benzisoxazol hydrochloride, 2.21 g (16 mmoles) of potassium carbonate and a catalytic amount of potassium iodide were suspended. The reaction mixture was refluxed for 18 hours, cooled to 20°C and filtered, and the filtrate was evaporated by reduced pressure distillation. Purification of the crude was performed on silica gel column using acetonitrile/methanol as eluent. 15 g of 6- [2- [4- (6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl]ethyl] -3- (4-methoxyphenyl) -7-methyl-5H-thiazolo[3,2-a]pyrimidin-5- one, mp 113.5-118.9°C. Examples 17-28: Following the same procedure as for the compound in Example 16 and starting from appropriate intermediates, the compounds in Table 4 were obtained.

Table 4

Code Cpds. (I) Ar R mp °C

FI-8544 Example 17 4-methylphenyl a 75-119

FI-8543 Example 18 benzo [1, 3] dioxol-5-yl a 209-213

FI-8545 Example 19 4-chlorophenyl a 79-98

FI-8546 Example 20 3,4-dichlorophenyl a 86-114

FI-8568 Example 21 3-chlorophenyl a 70-102

FI-8570 Example 22 3-methoxyphenyl a 71-111

FI-8569 Example 23 3-methylphenyl a 77-93

FI-8567 Example 24 2-chlorophenyl a 84-93

FI-8571 Example 25 3-trifluoromethylphenyl a 75-94

FI-8572 Example 26 2-fluorophenyl a 71-91

FI-8547 Example 27 phenyl b 65-86

FI-8548 Example 28 4-methoxyphenyl b 66-78 Example 29: Injectable solution

Formulation for 1 ampoule:

6- [2- [4- (6-fluoro-l,2-benzisoxazol-3 -yl) -1- piperidinyl]ethyl] -3- (4-fluorophenyl-7-methyl-5H- thiazolo[3,2-a]pyrimidin-5-one 5.0 mg methyl p-hydroxybenzoate 1.0 mg propyl p-hydroxybenzoate 0.1 mg Bidistilled water q.s 2.0 ml

Example 30: 1% oral solution

6- [2- [4- (6-fluoro-l,2-benzisoxazol-3-yl) - 1 ^■ piperidinyl] ethyl] -3- (4-fluorophenyl-7-methyl-5H- thiazolo[3,2-a]pyrimidin-5-one 1000 mg methyl p-hidroxibenzoato 135 mg propyl p-hidroxibenzoato 15 mg

Sorbitol 70 % 20 g Sodium saccharin 50 mg

Orange essence 0.25 ml

Distilled water q.s 100 ml

Example 31: Tablets

Formulation for 10 mg tablet:

6- [2- [4- (6-fluoro-l,2 -benzisoxazol -3-yl) - 1 - piperidinyl] ethyl] -3- (4-methylphenyl) -7-methyl-5H- thiazolo [3, 2-a]pyrimidin-5-one 10.0 mg

Corn starch 43.2 mg

Talc 6.0 mg Hydrogenated castor oil 2.0 mg

Lactose q.s 200.0 mg

Example 6 : Tablets

Formulation for 50 mg tablet:

6- [2- [4- (6-fluoro-l,2-benzisoxazol-3-yl) - 1 ^■ piperidinyl] ethyl] -3- (4-methylphenyl) -7-methyl-5H- thiazolo [3,2-a]pyrimidin-5-one 50.0 mg Corn starch 86.4 mg

Talc 12.0 mg

Hydrogenated castor oil 4.0 mg

Lactose q.s 400.0 mg

Claims

C l a i s

1. New 5H-thiazolo [3, 2-a]pyrimidin-5-one derivatives having the formula (I) :

(I) wherein Ar is phenyl optionally substituted by one or two groups selected from halogen, alkyl having from 1 to 4 carbon atoms, methylendioxy, alkoxy having from 1 to 4 carbon atoms, and trifluoromethyl; and R is a group selected from (a) or

(b) :

(a) (b) as well as their pharmaceutically acceptable addition salts.

2. New 5H-thiazolo [3, 2-alpyrimidin-5-one derivatives compounds of general formula (VI) :

(VI) wherein Ar is as defined for the foregoing structures .

3. The use of the 5H-thiazolo[3,2-a]pyrimidin-5-one derivatives as well as their pharmaceutically acceptable addition salts, according to claim 1, for preparing a pharmaceutical composition for the treatment of psychosis, schizophrenia and anxiety.

0 4. A pharmaceutical composition comprising a compound of claim l, optionally in combination with pharmaceutically acceptable carriers and/or adjuvants.

5. A method of treatment of psychosis, schizophrenia and 5 anxiety which comprises administering to a mammal an effective amount of a compound according to claim 1.

6. A process for preparing the 5H-thiazolo[3,2-a] pyrimidin-5-one derivatives as well as their pharmaceutically o acceptable additions salts, according to claim l, which comprises reacting 3-aryl-6- (2-substitutedethyl) -7-methyl- thiazolo[3,2-a]pyrimidin-5-one of general formula (II):

5

0

( ID wherein Ar is as defined for (I) and X is a halogen selected from chlorine, bromine or iodine, or a sulfonyloxy group, e.g., methylsulfonyloxy, p-toluensulfonyloxy and the like, with a piperidine of general formula (III) :

(III) wherein R is as defined for (I) .

7. A process for preparing the 5H-thiazolo[3,2-a] pyrimidin-5-one derivatives of claim 2 which comprises chlorinating a compound of formula (V)

Ar ."Λ^ςc CH —CH₂—OH

(V)

wherein Ar is as defined in claim 1.